



Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
Epoetin lambda	Anaemia Chronic kidney failure	Epex [®] brand of epoetin alfa (Janssen-Cilag)	Novicrit [®] (Sandoz)	01/08/2010 (pre-dated current PBAC approach to advice on 'a' flagging)
Filgrastim	Haematopoietic stem cell transplantation Chemotherapy induced neutropenia	Neupogen [®] (Amgen) 'a' flagged	Nivestim [®] (Pfizer) 'a' flagged	01/04/2011
			Zarzio [®] (Sandoz) 'a' flagged	01/09/2013
Infliximab	Ankylosing spondylitis Crohn's disease Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis	Remicade [®] (Janssen- Cilag) 'a' flagged	Inflectra [®] (Pfizer) 'a' flagged	01/12/2015
			Renflexis [®] (Merck Sharp and Dohme) 'a' flagged	01/08/2017
Follitropin alfa	Infertility treatment	Gonal-f [®] (Merck Serono Australia)	Bemfola [®] (Gedeon Richter)	01/08/2016
			Ovaleap [®] (Theramex) 'a' flagged	01/12/2021
Etanercept	Ankylosing spondylitis Psoriatic arthritis Psoriasis Rheumatoid arthritis Juvenile idiopathic arthritis (note this indication treated by Enbrel only)	Enbrel [®] (Pfizer) 'a' flagged	Brenzys [®] (Merck Sharp and Dohme) 'a' flagged	01/04/2017
Trastuzumab [†]	Breast cancer Gastric cancer	Herceptin [®] (Roche) (note this brand (IV) is no longer available on the PBS)	Ogivri [®] (Alphapharm)	01/08/2019
			Herzuma [®] (Celltrion)	01/11/2019

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
			Kanjinti® (Amgen)	01/12/2019
			Trazimera® (Pfizer)	01/05/2020
Rituximab†	CD20 positive follicular B-cell non-Hodgkin's lymphoma Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) CD20 positive non-Hodgkin's lymphoma Low-grade B-cell non-Hodgkin's lymphoma Chronic lymphocytic leukaemia Severe active rheumatoid arthritis Severe active microscopic polyangiitis	MabThera® (Roche) 'a' flagged (note this brand is no longer available on the PBS)	Riximyo® (Sandoz) 'a' flagged (s100)	01/10/2019
			Truxima® (Celltrion) 'a' flagged (s100)	01/01/2020
			Ruxience® (Pfizer) 'a' flagged (s100)	01/06/2022
Pegfilgrastim	Haematopoietic stem cell transplantation Chemotherapy induced neutropenia	Ristempa® (Juno) 'a' flagged (note this brand is no longer available on the PBS)	Ziextenzo® (Sandoz) 'a' flagged	01/03/2020
			Pelgraz® (Accord) 'a' flagged	01/08/2020
Adalimumab	Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa.	Humira® (AbbVie) 'a' flagged	Amgevita® (Amgen) 'a' flagged	01/04/2021
			Hadlima® (Arrow Pharma) 'a' flagged	01/04/2021
			Hyrimoz® (Sandoz) 'a' flagged	01/04/2021
			Idacio® (Fresenius Kabi) 'a' flagged	01/04/2021
			Yuflyma® (Celltrion) 'a' flagged	01/03/2023
			Adalicip (Cipla) 'a' flagged	01/01/2024

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
Bevacizumab†	Metastatic colorectal cancer Stage IV (metastatic) non-small cell lung cancer (NSCLC) Relapsed or recurrent glioblastoma Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer Advanced carcinoma of cervix	Avastin® (Roche) (note this brand is no longer available on the PBS)	Mvasi® (Amgen)	01/06/2021
			Bevaciptin® (Cipla)	01/11/2022
			Abevmy® (Alphapharm)	01/12/2022
Teriparatide	Osteoporosis in postmenopausal women; Primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fracture; and Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.	Forteo® (Eli Lilly) (note this brand is no longer available on PBS)	Terrosa® (Gedeon Richter)	01/10/2021
			Teriparatide Lupin® (Generic Health)	01/05/2024

Data correct as 1 May 2024.

* Refer to the Schedule of Pharmaceutical Benefits to identify indications for which the reference brand and biosimilar brand are available for subsidised access (all brands may not be available for all indications).

† The independent expert Pharmaceutical Benefits Advisory Committee (PBAC) recommended brands as substitutable biosimilars of the reference brands for the purposes of the Efficient Funding of Chemotherapy Program. Under section 33(2) of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011*, chemotherapy medicines supplied under the Efficient Funding of Chemotherapy Program may be substituted with a different brand of the same chemotherapy medicine. These medicines are not marked with 'a'-flags in the Schedule of Pharmaceutical Benefits.